LearnGlossaryMarketStocksSuperinvestorsSign in

CELC

Celcuity Inc.

Healthcare · $3.8B market cap

Verdict

We can't put a fair value on CELC right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth4.9% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-43.7%✗

Follow CELC

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds CELC. In Q2 2026, 1 added and 1 sold out. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$7.1M

6,250,000 shares

Moves in Q2 2026

Added: Howard Marks

Sold out: Polen Capital Management

About Celcuity Inc.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works